ERBB2 and cancer: Within the intrinsic subtypes, AKR1B10 expression is significantly higher in the HER2-enriched and basal-like breast cancers compared to luminal A and luminal B cancers (Fig. 2a) and analysis by receptor expression revealed significantly higher AKR1B10 expression in ER− compared to ER+ breast cancers, and in HER2+ compared to HER2− breast cancers (Fig. 2a).